Breviscapine alleviates NASH by inhibiting TGF-β-activated kinase 1-dependent signaling.

ABSTRACT:

Background and aims

NAFLD is a key component of metabolic syndrome, ranging from nonalcoholic fatty liver to NASH, and is now becoming the leading cause of cirrhosis and HCC worldwide. However, due to the complex and unclear pathophysiological mechanism, there are no specific approved agents for treating NASH. Breviscapine, a natural flavonoid prescription drug isolated from the traditional Chinese herb Erigeron breviscapus, exhibits a wide range of pharmacological properties, including effects on metabolism. However, the anti-NASH efficacy and mechanisms of breviscapine have not yet been characterized.

Approach and results

We evaluated the effects of breviscapine on the development of hepatic steatosis, inflammation, and fibrosis in vivo and in vitro under metabolic stress.

SUBMITTER: Lan T 

PROVIDER: S-EPMC9299589 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature